Amlo Biosciences
company
About
AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- £2.45M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
AMLo Biosciences has identified two proteins (AMBLor™) in the skin overlying the primary tumour that are lost in high-risk melanoma.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
£2.45M
Amlo Biosciences has raised a total of
£2.45M
in funding over 2 rounds. Their latest funding was raised on
Apr 21, 2022 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 21, 2022 | Series Unknown | £2.45M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Amlo Biosciences is funded by 1 investors.
Ascension Life Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Ascension Life Fund
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
